Internet publication
Hybrid adaptive immunity to SARS-CoV-2 protects against breakthrough infection after COVID-19 vaccination in ALSPAC participants
- Abstract:
- Immunological memory to vaccination and viral infection involves coordinated action of B and T-cells, thus integrated analysis of these two components is critical for understanding their contributions to protection against breakthrough infections (BI). We investigated cellular and humoral immune responses to SARS-CoV-2 infection and/or COVID-19 vaccination in participants from the Avon Longitudinal Study of Parents and Children (ALSPAC). The magnitude of antibody and T-cell responses following the second vaccine dose was associated with protection against BI in participants with a history of SARS-CoV-2 infection (cases), but not in infection-naïve controls. Youden’s index thresholds for protection against BI were calculated for all immune measures. Anti-Spike IgG (>666.4 BAU/mL) and anti-Nucleocapsid pan Ig (>0.1332 BAU/mL) thresholds combined were 100% specific and 83.3% sensitive for cases without BI over 8-months follow-up. Collectively these results point to the superior protective effect of hybrid immunity and have implications for the design of next-generation COVID-19 vaccines.
- Publication status:
- Published
- Peer review status:
- Not peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 10.1MB, Terms of use)
-
- Publisher copy:
- 10.1101/2024.06.14.24308948
Authors
+ Cancer Research UK
More from this funder
- Funder identifier:
- https://ror.org/054225q67
- Grant:
- 29019
+ UK Research and Innovation
More from this funder
- Funder identifier:
- https://ror.org/001aqnf71
- Grant:
- MR/V028448/1
- Host title:
- medRxiv
- Publication date:
- 2024-08-08
- DOI:
- EISSN:
-
2692-8205
- Language:
-
English
- Keywords:
- Pubs id:
-
2011243
- Local pid:
-
pubs:2011243
- Deposit date:
-
2024-12-18
Terms of use
- Copyright holder:
- Baum et al
- Copyright date:
- 2024
- Rights statement:
- ©2024 The Authors. The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
If you are the owner of this record, you can report an update to it here: Report update to this record